JP2011500727A - Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 - Google Patents

Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 Download PDF

Info

Publication number
JP2011500727A
JP2011500727A JP2010530173A JP2010530173A JP2011500727A JP 2011500727 A JP2011500727 A JP 2011500727A JP 2010530173 A JP2010530173 A JP 2010530173A JP 2010530173 A JP2010530173 A JP 2010530173A JP 2011500727 A JP2011500727 A JP 2011500727A
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
compound
group
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010530173A
Other languages
English (en)
Japanese (ja)
Inventor
ヤン シア，
クレイグ ディー． ボイル，
ウィリアム ジェイ． グリーンリー，
サミュエル チャッカラマニル，
チャールズ リー ジェイン，
アンドリュー ダブリュー． スタンフォード，
シン ダイ，
ジョエル エム． ハリス，
ベルナルド アール． ニュースタット，
サンソーシュ フランシス ニーラムカビル，
ウンメシュ ジー． シャー，
クレアー エム． ランキン，
ホン リュー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2011500727A publication Critical patent/JP2011500727A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010530173A 2007-10-22 2008-10-20 Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 Pending JP2011500727A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98167707P 2007-10-22 2007-10-22
PCT/US2008/080462 WO2009055331A2 (en) 2007-10-22 2008-10-20 Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013068780A Division JP5568154B2 (ja) 2007-10-22 2013-03-28 Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用

Publications (1)

Publication Number Publication Date
JP2011500727A true JP2011500727A (ja) 2011-01-06

Family

ID=40352187

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010530173A Pending JP2011500727A (ja) 2007-10-22 2008-10-20 Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
JP2013068780A Expired - Fee Related JP5568154B2 (ja) 2007-10-22 2013-03-28 Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013068780A Expired - Fee Related JP5568154B2 (ja) 2007-10-22 2013-03-28 Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用

Country Status (15)

Country Link
US (1) US8907095B2 (https=)
EP (1) EP2217596B8 (https=)
JP (2) JP2011500727A (https=)
KR (1) KR20100075643A (https=)
CN (1) CN101910151A (https=)
AR (1) AR068950A1 (https=)
AU (1) AU2008317057B8 (https=)
CA (1) CA2703203C (https=)
CL (1) CL2008003116A1 (https=)
IL (1) IL205251A0 (https=)
MX (1) MX2010004450A (https=)
PE (1) PE20091343A1 (https=)
TW (1) TW200922578A (https=)
WO (1) WO2009055331A2 (https=)
ZA (1) ZA201002959B (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730606A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
MX2011000664A (es) * 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
CA2747809A1 (en) * 2008-12-23 2010-07-01 Joel M. Harris Bicyclic heterocycle derivatives and methods of use thereof
WO2010106457A2 (en) * 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
AR076024A1 (es) * 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
FR2945534B1 (fr) * 2009-05-12 2012-11-16 Sanofi Aventis DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2945531A1 (fr) * 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
WO2010141932A1 (en) 2009-06-05 2010-12-09 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
AR077214A1 (es) 2009-06-24 2011-08-10 Neurocrine Biosciences Inc Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
WO2011017296A1 (en) * 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
WO2011053688A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
WO2011062889A1 (en) 2009-11-23 2011-05-26 Schering Corporation Pyrimidine ether derivatives and methods of use thereof
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
AR079493A1 (es) 2009-12-21 2012-02-01 Nippon Soda Co Compuesto de amina ciclica y acaricida
JP2013047188A (ja) * 2009-12-24 2013-03-07 Nippon Chemiphar Co Ltd Ｇｐｒ１１９作動薬
AR081721A1 (es) * 2010-02-25 2012-10-17 Nippon Soda Co Compuesto de amina ciclica y acaricida
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
US20130096141A1 (en) * 2010-06-18 2013-04-18 Bernard R. Neustadt Bicyclic heterocycle derivatives and methods of use thereof
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN102432598A (zh) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
CA2836487A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
KR101705390B1 (ko) 2012-06-25 2017-02-09 강원대학교산학협력단 이중환 구조를 갖는 신규한 ｇｐｃｒ 효능제
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
AR097794A1 (es) 2013-09-26 2016-04-13 Mnemosyne Pharmaceuticals Inc Moduladores octahidro-ciclopenta[c]pirrol negativos de nr2b
CR20170077A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
CA3081424A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Spirocyclic compounds as farnesoid x receptor modulators
CN111630051B (zh) 2017-11-01 2023-12-26 百时美施贵宝公司 作为法尼醇x受体调节剂的烯烃螺环化合物
CN111278817B (zh) 2017-11-01 2023-05-16 百时美施贵宝公司 作为法尼醇x受体调节剂的多环化合物
JP7264906B2 (ja) 2017-11-01 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
PE20201170A1 (es) 2017-11-01 2020-10-28 Bristol Myers Squibb Co Compuestos biciclicos en puente como moduladores del receptor farnesoide x
US10865194B2 (en) 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
KR20210129684A (ko) 2019-02-15 2021-10-28 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서 유용한 치환된 아미드 화합물
CN113677666A (zh) 2019-02-15 2021-11-19 百时美施贵宝公司 作为类法尼醇x受体调节剂的经取代的双环化合物
CN113677659B (zh) 2019-02-15 2024-09-06 百时美施贵宝公司 可用作类法尼醇x受体调节剂的经取代的酰胺化合物
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
PE20220597A1 (es) 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
US11518758B2 (en) 2019-05-10 2022-12-06 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PE20221083A1 (es) 2019-06-17 2022-07-05 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
CN116082188A (zh) * 2023-02-14 2023-05-09 都创(上海)医药开发有限公司 一种以3-氟-4-氨基苯腈为原料合成4-溴-3-氯-5-氟苯腈的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063071A1 (en) * 2005-12-01 2007-06-07 N.V. Organon 8-azabicyclo[3.2.1]octane derivatives useful as monoamine reuptake inhibitors
JP2007528856A (ja) * 2003-07-11 2007-10-18 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝モジュレーターとしての三置換アリールおよびヘテロアリール誘導体ならびにそれらに関連する障害の予防および治療

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
WO1985005029A1 (en) 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
CA1256116A (en) 1984-09-20 1989-06-20 Joseph E. Moore Fungicidal n-cyanoalkyl-n-haloalkylthio sulfonamides
US5642868A (en) 1990-05-02 1997-07-01 The United States Of America As Represented By The Secretary Of The Navy Ceramic material
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
JP2000509042A (ja) 1996-04-23 2000-07-18 イーライ・リリー・アンド・カンパニー ヘテロサイクリック化合物群
CA2269128C (en) 1996-10-30 2005-01-11 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
CN1275596C (zh) 1997-05-14 2006-09-20 阿特罗吉尼克斯公司 普罗布考单酯在制备用于治疗心血管疾病和炎性疾病的药物中的应用
ATE251465T1 (de) 1998-07-31 2003-10-15 Novo Nordisk As In-vitro stimulation von beta zellen vermehrung
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
WO2000038727A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
WO2000038721A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
FR2802817B1 (fr) 1999-12-23 2002-10-11 Centre Nat Rech Scient Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
EP1338651B9 (en) 2000-12-01 2007-05-09 Astellas Pharma Inc. Method of screening remedy for diabetes
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
WO2004076413A2 (en) 2003-02-24 2004-09-10 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism
EP1660477B1 (en) 2003-08-07 2008-12-10 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
PL1756084T3 (pl) 2004-06-04 2009-06-30 Arena Pharm Inc Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie zaburzeń z metabolizmem związanych
EP1797040A1 (en) 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7723342B2 (en) 2005-05-17 2010-05-25 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US20100160359A1 (en) 2005-09-16 2010-06-24 Arena Pharmaceuticals, Inc. Modulators of Metabolism and the Treatment of Disorders Related Thereto
LT1976828T (lt) * 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528856A (ja) * 2003-07-11 2007-10-18 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝モジュレーターとしての三置換アリールおよびヘテロアリール誘導体ならびにそれらに関連する障害の予防および治療
WO2007063071A1 (en) * 2005-12-01 2007-06-07 N.V. Organon 8-azabicyclo[3.2.1]octane derivatives useful as monoamine reuptake inhibitors

Also Published As

Publication number Publication date
CA2703203A1 (en) 2009-04-30
PE20091343A1 (es) 2009-09-18
EP2217596A2 (en) 2010-08-18
EP2217596B1 (en) 2013-01-30
JP2013129675A (ja) 2013-07-04
AU2008317057B8 (en) 2014-02-13
IL205251A0 (en) 2010-12-30
AU2008317057B2 (en) 2014-02-06
AR068950A1 (es) 2009-12-16
CL2008003116A1 (es) 2010-02-05
KR20100075643A (ko) 2010-07-02
EP2217596B8 (en) 2013-11-20
WO2009055331A2 (en) 2009-04-30
CN101910151A (zh) 2010-12-08
CA2703203C (en) 2015-12-15
WO2009055331A3 (en) 2009-07-30
AU2008317057A1 (en) 2009-04-30
JP5568154B2 (ja) 2014-08-06
US20110212938A1 (en) 2011-09-01
AU2008317057A8 (en) 2014-02-13
TW200922578A (en) 2009-06-01
US8907095B2 (en) 2014-12-09
MX2010004450A (es) 2010-05-05
ZA201002959B (en) 2011-11-30

Similar Documents

Publication Publication Date Title
JP5568154B2 (ja) Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
US8580807B2 (en) Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
US8815876B2 (en) Bicyclic heterocycle derivatives and methods of use thereof
US9301929B2 (en) Substituted biaryl derivatives and methods of use thereof
US8410122B2 (en) Bicyclic heterocycle derivatives and methods of use thereof
US9409918B2 (en) Bridged bicyclic piperidine derivatives and methods of use thereof
US20110118286A1 (en) Bicyclic heterocycle derivatives and their use as gpcr modulators
US20120232073A1 (en) Fused bicyclic pyrimidine derivatives and methods of use thereof
JP2011528365A (ja) Ｇｐｒ１１９モジュレーターとしての二環式ヘテロ環誘導体およびそれらの使用方法
US8722882B2 (en) Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes
US20120040975A1 (en) Bridged bicyclic heterocycle derivatives and methods of use thereof
WO2008130581A1 (en) Pyrimidinone derivatives and methods of use thereof
JP2011520969A (ja) 二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用
WO2010075273A1 (en) Bicyclic heterocycle derivatives and methods of use thereof
US8912206B2 (en) Pyrimidine ether derivatives and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130318

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130328

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130806